QuickView for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=816C1DB4C8394B8E19A693B66C06C1A1;jsessionid=192BA595AF6DAD169ACDFE5357F38A2D;jsessionid=05EE139BC130B63283A2909B3C1F1231;jsessionid=0B1680C032E48B018C9C909E7AE2E77E;jsessionid=0FF738C2287AAF7712E018F9DA2007AE;jsessionid=2BED923FAC59C6BA663AC6D417E18729 (gene)

1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistan…
2. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
3. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Mat…
4. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
5. Cooperative Nucleotide Binding in Hsp90 and Its Regulation by Aha1.

There were no clinical trials for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=816C1DB4C8394B8E19A693B66C06C1A1;jsessionid=192BA595AF6DAD169ACDFE5357F38A2D;jsessionid=05EE139BC130B63283A2909B3C1F1231;jsessionid=0B1680C032E48B018C9C909E7AE2E77E;jsessionid=0FF738C2287AAF7712E018F9DA2007AE;jsessionid=2BED923FAC59C6BA663AC6D417E18729